Amgen and Horizon can close their $28B deal after resolving lawsuit by the FTC
Amgen has settled with the Federal Trade Commission after the US regulator in May had tried blocking the California drugmaker’s proposed nearly $28 billion acquisition of Horizon Therapeutics.
The deal is expected to close early next quarter now, the companies said Friday morning.
Amgen and Horizon entered into a consent order agreement with the FTC, which will resolve the agency’s pending administrative lawsuit, the companies said Friday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.